Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gut Microbiome and Physical Abilities
NCT05024188Recruiting
- Sponsor
- Shamir Medical Center
- Start
- Jun 2022
- Primary completion
- Dec 2028
- Modality
- Small Molecules, Live Biotherapeutic Products
- Countries
- 1
01
Overview
Randomised trial of autologous fecal microbiota transplantation, ciprofloxacin and metronidazole (3 arms), sponsored by Shamir Medical Center. Primary endpoints: Microbiome Profiling at 1 month and Physical ability at 1 month. Started Jun 2022; status: recruiting.
02
Drugs
autologous fecal microbiota transplantationciprofloxacinmetronidazole
Beyond the preview
Go deeper on NCT05024188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05024188.